https://www.theedgemarkets.com/article/vaccine-ven
Post# of 36537
Mechanical and electrical engineering works specialist Bintai Kinden has seen its share price rise more than fourfold, after it signed an MoU with vaccine research firm NuGenerex Immuno-Oncology (Generex) to fund and manage a synthetic peptide vaccine for Covid-19. Generex is principally involved in robust research and development into the creation of on-demand peptide vaccines to control pandemic viruses.